Short answer
Solventum (SOLV) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.9B (down 7.0% year over year) with net income of −$12M.
Q3 2026 key financials · XBRL
- Revenue
- $1.9B
- −7.0% YoY · −11.8% QoQ
- Net income
- −$12M
- −100.9% YoY · −113.0% QoQ
- Operating margin
- 3.4%
- Gross margin
- 54.5%
- EPS (diluted)
- −$0.06
- −100.8% YoY · −111.3% QoQ
Source: XBRL data from the Solventum (SOLV) Q3 2026 10-Q on SEC EDGAR. USD.
Solventum Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1,949M, down 7.0% YoY from $2,096M, reflecting ERP-related customer destocking
- Operating margin 3.5% vs 80.6% YoY, with $1.5B prior-year business-sale gain
- Best segment Health Information Systems: sales up 3.3%, operating margin 41.7% vs 38.8%
- Worst segment Dental Solutions: sales down 6.7%, operating margin 20.1% vs 25.7%
- Cash $451M vs $878M at December 31, 2025, with $118M of $120M tariff refunds recovered
Risk Factors
- Newly added strategic risk: health information systems review may fail to produce or complete a strategic alternative
- Most material update: review creates customer and employee uncertainty while diverting management attention
- Operational risk: review-related costs may arise regardless of transaction success
- Financial risk: unsuccessful alternatives could adversely affect cash flows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Solventum quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.